Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-09-24Clinical Trial Update: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib with rituximab and lenalidomide in previously untreated stage II-IV follicular lymphom…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating the effect of Vitamin D on progression-free survival in indolent non-Hodgkin lymphoma has completed with results po…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab [Phase 3]
A Phase 3 trial comparing Bendamustine plus Rituximab vs CHOP plus Rituximab in various non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]
Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity ac…
-
CLINICAL_TRIALS trial_result · 2024-06-05Clinical Trial Update: IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial update on IBI376 in relapsed or refractory follicular lymphoma and marginal zone lymphoma. The study status is comple…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 trial update for ICP-022 in relapsed/refractory marginal zone lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]
The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]
Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were post…
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating ublituximab followed by response-driven addition of umbralisib for treatment-naive follicular lymphoma or marginal …
-
CLINICAL_TRIALS trial_result · 2023-06-23Clinical Trial Update: Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial assessing efficacy and safety of umbralisib in non-follicular indolent non-Hodgkin lymphoma has completed with results posted …
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]
A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma [Phase 2]
Phase 2 study of zanubrutinib in marginal zone lymphoma has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) [Phase 2]
A Phase 2 study evaluating INCB050465 in relapsed or refractory marginal zone lymphoma has completed, and results were posted on February 10…